摘要
目的:探讨急性白血病患者白血病细胞DNA拓扑异构酶Ⅱ(DNATopoⅡ)活性与多药耐药的关系。方法:采用溴乙锭荧光法对17例初治化疗前及20例化疗后的急性白血病患者外周血或骨髓白血病细胞DNATopoⅡ活性进行测定,采用抗多药耐药单抗JSBⅠ检测18例化疗后患者p糖蛋白表达,采用RTPCR法检测mdr1基因表达。结果:白血病患者化疗前组TopoⅡ活性(0.6415±0.0561)较健康对照组(0.2304±0.0591)显著增高(P<0.005)。化疗后患者白血病细胞TopoⅡ活性(0.3563±0.1011)较化疗前组显著降低(P<0.05)。15例临床疗效差,其中12例p170及mdr1基因表达阳性、3例表达阴性,而TopoⅡ活性均降低。结论:TopoⅡ活性下降可能是患者对抗肿瘤药表现耐药的另一重要原因。
Objective:To explore the relationship between DNA topoisomerase Ⅱ (Topo Ⅱ) activity and multidrug resistance in acute leukemia(AL). Methods: Topo Ⅱ activities were measured in peripheral blood or bone marrow leukemia cells from 17 pretreated patients and 20 after combination chemotherapy by fluorometric assay. In the same time, multidrug resistant p glycoprotein expression was detected by immunohistochemistry using JSB 1 monoclonal antibody and mdr 1 gene expression was assayed by RT PCR in 18 post chemotherapy patients. Results: Topo Ⅱ activities were significantly higher in pretreated AL patients (0.6415±0.0561) than in healthy blood donors (0.2304±0.0591)(P<0.005) and significantly lower in post chemotherapy patients (0.3563±0.1011) than in pretreated ones (P<0.005). Among 15 poorly responsed patients, 12 were p170 positive and mdr 1 overexpression, 3 case were p170 negative. Topo Ⅱ activity was also decreased in these poor responsers. Conclusion: Decreased Topo Ⅱ activity may be another factor in multidrug resistance.
出处
《中华血液学杂志》
CAS
CSCD
北大核心
1998年第9期470-472,共3页
Chinese Journal of Hematology